Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;16(9):903-7.
doi: 10.1038/mp.2011.52. Epub 2011 May 10.

APOE and Alzheimer disease: a major gene with semi-dominant inheritance

Affiliations

APOE and Alzheimer disease: a major gene with semi-dominant inheritance

E Genin et al. Mol Psychiatry. 2011 Sep.

Abstract

Apolipoprotein E (APOE) dependent lifetime risks (LTRs) for Alzheimer Disease (AD) are currently not accurately known and odds ratios alone are insufficient to assess these risks. We calculated AD LTR in 7351 cases and 10 132 controls from Caucasian ancestry using Rochester (USA) incidence data. At the age of 85 the LTR of AD without reference to APOE genotype was 11% in males and 14% in females. At the same age, this risk ranged from 51% for APOE44 male carriers to 60% for APOE44 female carriers, and from 23% for APOE34 male carriers to 30% for APOE34 female carriers, consistent with semi-dominant inheritance of a moderately penetrant gene. Using PAQUID (France) incidence data, estimates were globally similar except that at age 85 the LTRs reached 68 and 35% for APOE 44 and APOE 34 female carriers, respectively. These risks are more similar to those of major genes in Mendelian diseases, such as BRCA1 in breast cancer, than those of low-risk common alleles identified by recent GWAS in complex diseases. In addition, stratification of our data by age groups clearly demonstrates that APOE4 is a risk factor not only for late-onset but for early-onset AD as well. Together, these results urge a reappraisal of the impact of APOE in Alzheimer disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare no conflict of interest.

References

    1. Saunders AM, Strittmatter WJ, Schmechel D, St George-Hyslop P, Pericack-Vance MA, et al. Association of ApolipoproteinE allele 4 with late-onset familial and sporadic Alzheimer disease. Neurology. 1997;60:439–446. - PubMed
    1. Farrer LA, Cupples A, Haines JH, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex and ethnicity on the association between Apolipoprotein E genotype and Alzheimer Disease. JAMA. 1997;278:1349–1555. - PubMed
    1. Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A, et al. Association of CR, CLU and PICALM with Alzheimer’s disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet. 2010;19:3295–3301. - PMC - PubMed
    1. Bickeboller H, Campion D, Brice A, Amouyel P, Hannequin D, Didierjean O, et al. Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Am J Hum Genet. 1997;60(2):439–46. - PMC - PubMed
    1. Myers RH, Schaefer EJ, Wilson P, D’Agostino R, Ordovas JM, Espino A, et al. Apolipoprotein E element 4 association with dementia in a population based study: the Framingham Study. Neurology. 1996;46:673–677. - PubMed

Publication types